Introduction of exogenous HSV-TK suicide gene increases safety of keratinocyte-derived induced pluripotent stem cells by providing genetic "emergency exit" switch by Sułkowski, Maciej et al.
 International Journal of 
Molecular Sciences
Article
Introduction of Exogenous HSV-TK Suicide Gene
Increases Safety of Keratinocyte-Derived Induced
Pluripotent Stem Cells by Providing Genetic
“Emergency Exit” Switch
Maciej Sułkowski ID , Paweł Konieczny, Paula Chlebanowska and Marcin Majka *
Department of Transplantation, Faculty of Clinical Immunology and Transplantation, Institute of Pediatrics,
Collegium Medicum Jagiellonian University, Wielicka 265, 30-663 Kraków, Poland;
maciek.sulkowski@uj.edu.pl (M.S.); pawel.konieczny@outlook.com (P.K.); paulalota0@gmail.com (P.C.)
* Correspondence: mmajka@cm-uj.krakow.pl; Tel.: +48-12-659-15-93
Received: 7 December 2017; Accepted: 5 January 2018; Published: 9 January 2018
Abstract: Since their invention in 2006, induced Pluripotent Stem (iPS) cells remain a great promise
for regenerative medicine circumventing the ethical issues linked to Embryonic Stem (ES) cell
research. iPS cells can be generated in a patient-specific manner as an unlimited source of various
cell types for in vitro drug screening, developmental biology studies and regenerative use. Having
the capacity of differentiating into the cells of all three primary germ layers, iPS cells have high
potential to form teratoma tumors. This remains their main disadvantage and hazard which, until
resolved, prevents utilization of iPS cells in clinic. Here, we present an approach for increasing
iPS cells safety by introducing genetic modification—exogenous suicide gene Herpes Simplex Virus
Thymidine Kinase (HSV-TK). Its expression results in specific vulnerability of genetically modified
cells to prodrug—ganciclovir (GCV). We show that HSV-TK expressing cells can be eradicated both
in vitro and in vivo with high specificity and efficiency with low doses of GCV. Described strategy
increases iPS cells safety for future clinical applications by generating “emergency exit” switch
allowing eradication of transplanted cells in case of their malfunction.
Keywords: induced Pluripotent Stem (iPS); suicide gene therapy; genetic safeguarding
1. Introduction
Since their invention, induced Pluripotent Stem cells (iPS) [1,2], remain a great promise for
regenerative medicine. Their greatest advantage is a possession of all traits of Embryonic Stem
cells (ES) [3] while being free of their main limitation—ethical issues concerning disruption of
human embryos during isolation. iPS cells are generated by cellular reprogramming of somatic
cells into pluripotency [4] and can be obtained from virtually any cell type. This also implies
that they can be created in a patient-specific manner and are able to deliver autologous cells of
interest for transplantation. iPS cells enable generation of patient-derived in vitro models, which can
serve for personalized drug screening [5,6]. Patient-specific iPS cells were generated for Parkinson’s
disease, Huntington’s disease, Gaucher’s disease, Becker’s and Duchenne’s muscular dystrophy,
Down’s syndrome, amyotrophic lateral sclerosis, LEOPARD syndrome, diabetes type I and other
disorders [7–10]. It was shown that iPS-derived somatic cells recapitulate symptoms/phenotypes of
diseases in vitro [11–13] thus offering a personalized model for in vitro drug screening. Moreover, they
were also able to improve symptoms in numerous animal models of diseases [7–9].
Originally, iPS cells were generated by viral transduction [1,2]. Such strategy is not optimal as it
generates risk of uncontrolled insertional mutagenesis. Thus, several safer, non-integrating methods
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have been proposed since 2006. These include use of recombinant proteins [14,15], transposons [16,17]
mRNA [18], DNA plasmids [19], non-integrating viruses [20] or chemical stimulation [21,22] (reviewed
in [23]). These reprogramming methods increase safety of iPS cells.
Despite of all advantages of iPS cells, they still cannot be used in clinic until their major
drawback—tumorigenesis risk—is eliminated. As pluripotency is a double-edged sword, iPS cells
are able to form teratomas—tumors built of all three germ layers [24–26]. A possible approach to
overcome this issue is to safeguard iPS cells by equipping them with suicide gene which selectively
sensitizes genetically modified cells to normally non-toxic compounds. An example of such strategy
is suicide gene therapy with Herpes Simplex Virus Thymidine Kinase (HSV-TK) and its substrate,
antiviral medication, ganciclovir (GCV, 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine). This approach
was proved to be highly effective anti-cancer therapy in vitro [27–29] and in vivo [30,31] as well as in a
clinical trial [32].
Thymidine kinase (EC 2.7.1.21) is the key phosphotransferase in the pyrimidine salvage pathway
catalyzing specific transfer of γ-phosphate from ATP to thymidine producing dTMP [33]. It is present
in two forms in most mammalian cells. Viral HSV-TK, introduced into mammalian cells during viral
infection, unlike specific cellular thymidine kinase, catalyzes reactions of various substrates including
pyrimidine analogs (such as thymidine and deoxycytidine), and purine analogs (acyclovir, ganciclovir,
buciclovir and penciclovir). GCV is phosphorylated to GCV-monophosphate by HSV-TK and
further by cellular kinases to GCV-triphosphate, which is a competitive inhibitor of deoxyguanosine
triphosphate (dGTP) and incorporates into DNA inhibiting DNA replication [34]. Additionally, toxic
GCV-triphosphate can be efficiently transferred to adjacent cells resulting in elimination of unmodified
cells of the same type in, so called, bystander effect [35]. Transport of active GCV metabolite to
adjacent cells is mediated by gap junctions—intercellular channels built from connexins—which allows
direct diffusion of ions and small molecules (of mass up to 2 kDa) between neighboring cells [36,37].
This transfer induces similar susceptibility of adjacent cells to GCV and can be so efficient that as few
as 10% of malignant cells expressing HSV-TK gene in population is sufficient to eliminate all tumor
cells [35].
Here, we present a strategy to increase iPS cells safety by incorporating “safety switch” or
“emergency exit” which allows efficient elimination of all iPS cells genetically modified to express
HSV-TK by simple addition of non-toxic prodrug GCV when needed. We generated iPS cells by
reprogramming plucked-hair keratinocytes using safe method—transduction with non-integrating
Sendai virus vector. Generated keratinocytes-derived-iPS (kiPS) cells were characterized and
subsequently genetically modified with lentiviral vectors harboring HSV-TK. For proof-of-concept
studies, lentiviral transduction was used, however in future studies this approach will be replaced
with safer method of transgene delivery. iPS cells expressing HSV-TK were efficiently eliminated both
in vitro and in vivo upon administration of CGV. This proves efficiency of suicide gene therapy of iPS
cells and feasibility to eradicate all genetically modified transplanted cells upon their “rogue” behavior.
2. Results
2.1. Reprogramming of Keratinocytes from Plucked Hair
Keratinocytes from plucked hair seem to be very promising cell type for reprogramming.
Acquisition of hairs is simple and non-invasive. Between ten and twenty hairs were obtained from
healthy volunteers. Sufficient number of cells for reprogramming by direct outgrowth from hair outer
root sheath (ORS), marked with arrow in Figure 1A, were obtained in 2–3 weeks. Isolated cells were
expanded (Figure 1B) and cryopreserved. To achieve the highest safety of cellular reprogramming,
we used non-integrating Sendai virus-based method. Within four days after infection (Figure 1C),
morphology of infected keratinocytes altered and became more epithelial (Figure 1D), which is an
indication of mesenchymal-to-epithelial transition occurring in early stages of reprogramming [38].
During first days after infection moderate cytotoxicity was observed. First colonies with morphology
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typical for pluripotent cells, i.e., tightly packed small cells with high nucleus/cytoplasm ratio,
appeared around 14 days post infection (Figure 1E). These colonies quickly stopped dividing and cells
dispersed suggesting that they were incompletely reprogramed pre-iPS colonies. After Day 18, fully
reprogrammed iPS colonies started to appear.
Twelve colonies with most iPS-like morphology (Figure 1F), growth rate and expression of
alkaline phosphatase (Figure 1G) were transferred to separate dishes between Day 28 and Day 35 post
infection. Ten colonies gave start to keratinocytes-derived-iPS (kiPS) cell lines. This implies efficiency
of reprograming at a level of 0.01%, which is lower than described for Sendai virus reprograming
of neonatal fibroblasts. Acquired kiPS cell lines were expanded until passage 10 before subsequent
analyses [20].
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Figure 1. Isolation and reprogramming of plucked-hair keratinocytes: (A) keratinocytes migrating
from plucked-hair outer root sheath (ORS), ORS is marked with white arrow; (B) morphology of
isolated keratinocytes after their subculture and expansion; (C) isolated keratinocytes one day before
infection; (D) morphology of transduced keratinocytes changed to epithelial within four days after
infection; (E) first iPS-like colonies appeared around Day 14 post infection; (F) typical morphology of
transferred colonies on Days 28–35; (G) colonies expressed alkaline phosphatase (green fluorescence);
(A–E) magnification 200×, white bars represent 50 µm; and (F,G) magnification 10×, white bars
represent 100 µm.
Int. J. Mol. Sci. 2018, 19, 197 4 of 16
2.2. Characteristic of Acquired kiPS Cell Lines
Three out of ten acquired kiPS cell lines were examined for their pluripotency markers
and teratoma formation ability. All analyzed cell lines possessed high expression of embryonic
pluripotency surface markers (SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81) as compared to positive
control—commercially available and characterized protein-iPS (piPS ) line (Figure 2A). They also
possessed characteristic morphology—colonies of tightly packed small cells with large nuclei and
distinct borders—and unlimited growth potential (cultured for at least 50 passages).
Obtained cell lines also possessed endogenous expression of pluripotency markers on the level
of mRNA, namely OCT4, NANOG, C-MYC, and telomerase (TERT) (Figure 2B). Viral transgenes
(Sendai virus genome, SeV and vc-Myc) were silenced at passage 15 suggesting total loss of these viral
transgenes at this point (Figure 2C) and fully endogenic expression of pluripotency genes.
Moreover, acquired kiPS cell lines could form teratomas in immunodeficient mice (Figure 3A).
Histopathological analysis of tumors revealed presence of all three germ layers. Structures
characteristic for cartilage (Figure 3B), secreting epithelium (Figure 3C), and stratified epithelium
(Figure 3D) could be observed within generated tumors proving pluripotency of kiPS cell lines.
Characteristic image of teratoma formed by kiPS (Figure 3A) cell line was similar to one formed by
control piPS cell line (Figure 3E).
These results suggest successful reprograming of keratinocytes and full pluripotency of
established vector-free kiPS cell lines.
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Figure 2. Acquired keratinocytes-derived-iPS (kiPS) cell lines express endogenous pluripotency
markers and silence viral transgenes: (A) kiPS cell lines expressed surface antigens, i.e., SSEA-3,
SSEA-4, TRA-1-60, and TRA-1-81; and (B) pluripotency genes, i.e., OCT-4, NANOG, TETR, C-MYC,
characteristic for pluripotent stem cells. (C) Viral transgenes (SeV, vC-MYC) in generated kiPS cell
lines were silenced at passage 15. piPS, commercially available protein-iPS cell line; sv-iPS, iPS cell
line on early passage generated with Sendai Virus; SeV, primers specific for Sendai Virus genome;
vC-MYC, primers specific for viral transgenic C-MYC; TERT, telomerase; GAPDH, housekeeping gene,
glyceraldehyde 3-phosphate dehydrogenase; BF, bright field. All images in (A): magnification 400×,
white bars represent 50 µm.
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2.3. Genetic Modification of kiPS Cell Lines
kiPS cells were infected using lentiviral particles introducing GFP as a control and
GFP-ires-HSV-TK construct with MOI = 3 and selected for two weeks. Established cell lines kiPS
GFP (expressing GFP, Figure 4A) and kiPS HSV-TK (expressing GFP and HSV-TK, Figure 4B) were
developed with moderate purity of 40% and 80%, respectively (Figure 4C). To increase purity of
genetically modified population for in vivo studies, GFP-positive cells were sorted by FACS Aria
and purity of at least 80% was achieved for both cell lines (Figure 4D). It is noteworthy that
genetic modification did not alter the morphology of kiPS cell lines and only slightly decreased
proliferation rate of kiPS HSV-TK cell line both in vitro and in vivo visible in supplementary Figure S1.
We assumed that the phenomenon was caused by presence of exogenous kinase (HSV-TK) which
might non-specifically phosphorylate multiple cellular targets. We observed similar phenomenon in
rhabdomyosarcoma cell line [29].
Acquired data suggest efficient introduction of HSV-TK and GFP expression into established kiPS
cell lines.
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Figure 4. Genetic modification of kiPS cell lines. Genetically modified kiPS cell line express: GFP (A);
or GFP and HSV-TK (B). (C) Purity of genetically modified cell lines after antibiotic selection analyzed
by flow cytometry. (D) Purity of genetically modified cell after cell sorting. (A) Magnification 200×,
white bars represent 50 µm; and (B) magnification 400×, white bars represent 50 µm.
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2.4. Successful Suicide Gene Therapy of kiPS Cells In Vitro an In Vivo
Our main goal was to introduce genetic modification allowing efficient elimination of transplanted
cells upon their undesired behavior. Administration of prodrug non-toxic for normal cells would
cause elimination of all transplanted cells and thus increase safety of iPS in clinical application.
Genetically modified, HSV-TK expressing cells were highly sensitive to all applied doses of ganciclovir
(Figure 5A,B). After only four days of 0.1 µg/mL ganciclovir treatment, virtually all HSV-TK expressing
cells were eliminated in vitro proving high efficiency of applied suicide gene therapy. It has to be
noticed that, apart from mild non-specific toxic effect of 10 µg/mL ganciclovir, no cytotoxic effect was
observed in kiPS WT and kiPS GFP line suggesting high specificity of HSV-TK+GCV system (Figure 5A).
Moreover, thanks to described bystander effect, unmodified cells within unsorted population of kiPS
HSV-TK cells were also efficiently eliminated within four days. Figure 5B illustrates that all cells in
culture are efficiently eliminated when only 40% of cells in population express HSV-TK (unsorted kiPS
HSV-TK population). These data are consistent with our previous observations in rhabdomyosarcoma,
where only 20% of HSV-TK expressing cells in population were enough to eradicate basically every
cell in the culture by ganciclovir treatment [29].
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Figure 5. anciclovir efficiently eli inates SV-TK expressing kiPS cells in vitro. ( ) Four days of
treat ent with 0.1, 1 and 10 µg/ L ganciclovir (GCV). All sorted HSV-TK-expressing kiPS cells were
eliminated while control cells (kiPS T and kiPS GFP) remained intact despite mild non-specific
toxicity in highest GCV dose. (B) Four days of treatment with 0.1, 1 and 10 µg/mL ganciclovir (GCV).
Almost all unsorted HSV-TK-expressing kiPS cells were eliminated while control cells (kiPS WT and
kiPS GFP) remained intact. All images: magnification 100×, and white bars represent 100 µm.
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The suicide gene therapy was also successful in in vivo experiments (Figure 6). Compared with
control group (kiPS HSV-TK + PBS), size (Figure 6A) and weight (Figure 6B) of tumors formed by kiPS
HSV-TK cells drastically decreased upon administration of GCV. Tumors formed by kiPS HSV-TK
cells were almost completely eradicated upon systemic administration of GCV (Figure 6C). Moreover,
no systemic toxicity was observed upon this treatment, showing the high specificity of the described
approach. Growth of tumors formed by control cell line (kiPS WT and GFP) were not abrogated by
administration of GCV (Figure 6B and Figure S1).
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After formation of tumors mice were daily injected with saline (PBS) or 50 mg/kg ganciclovir (GCV)
intraperitoneally for 42 days. Growth of kiPS HSV-TK teratomas was abrogated after administration
of ganciclovir (start of treatment is pointed by black arrow). (A) kiPS HSV-TK tumor volume
during experiment; (B) final tumor mass; (C) dissected tumors; and (D) histopathologic images
of kiPS HSV-TK-formed teratomas containing th e g rm layer derivatives: (E) cartilage; (F) secreting
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data for one of two replicates, in each n = 3. White and black squares in (C) represent 5 mm; and
(D–G) magnification 100×, bars represent 100 µm.
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It is worth mentioning that genetic modification introducing HSV-TK expression did not alter
any properties or quality of established kiPS. They retained characteristic morphology, growth rate,
formed embryoid bodies and could form teratomas (Figure 6D). These observations suggest that their
potential for differentiation is not compromised and their pluripotency is sustained. Performed genetic
modification introducing exogenous expression of HSV-TK did not change pluripotency status or
biology of generated kiPS cells.
Acquired results demonstrate high efficiency and specificity of described iPS suicide gene therapy,
both in vitro and in vivo. Presented concept increases iPS cells safety for future clinical application.
Introduction of a “safety switch” allows efficient elimination of transplanted cells upon previously
unexpected necessity.
3. Discussion
iPS cells are a great promise for future regenerative therapies of many diseases. However, their
pluripotency is also their greatest hazard, as their tumorigenic potential must be overcome before they
will advance to clinic.
Here we show that introduction of genetic “trigger” allowing efficient elimination of all
transplanted cells can increase safety of iPS cells in future clinical applications by safeguarding
their main risk—tumorigenesis.
Our safeguarded kiPS cell lines were developed by reprogramming of plucked hair keratinocytes,
an alternative and convenient source of somatic cells which can deliver cells for reprogramming in
easy and non-invasive manner. iPS cells can be generated by reprograming virtually any somatic cell
type. Most desirable are cells which can be acquired by non-invasive method. As harvesting skin
fibroblast by biopsies can be painful and collecting blood samples is not always possible (patients’
needle phobia or viral infection), plucking hair for isolation of keratinocytes seems to be a legitimate
option. Skin keratinocytes are known to be easier to reprogram than skin fibroblast because of their
endogenous expression of KLF4 and c-MYC [39].
Non-integrating, episomal viral vector based on Sendai virus [40,41] was used to reprogram
acquired keratinocytes. This method provides safe and efficient reprogramming technique. Although
our reprogramming efficiency (0.01%) was lower than described for reprogramming of neonatal
fibroblast with Sendai virus [20] and keratinocytes with retroviral vectors [39], it appeared sufficient to
deliver fully functional kiPS cell lines. Decreased efficiency of reprogramming might have been caused
by suboptimal protocol of keratinocytes infection with Sendai virus (to our knowledge previously
unpublished) and more differentiated/senescence state of keratinocytes acquired from hair plucked
form adult individuals than neonatal cells [42].
Generated kiPS cells lines were efficiently genetically modified by lentiviral transduction to
express transgene of interest—HSV-TK—and reporter gene—GFP. It has to be clearly noted that kiPS
cells transduction did not interfere with their pluripotency as modified cells were able to efficiently
form teratomas (Figure 6D), which proves their pluripotency [43]. Thus, genetic modification of kiPS
cells is neutral for their biology involving growth rate, differentiation potential and pluripotency
features. Unfortunately, use of lentiviral vectors for generation of genetically safeguarded iPS cells
is not the optimal solution as it generates risk of insertional mutagenesis [44] which is not desired
in clinical application of stem cells. Lentiviral vectors were used here as a method of choice for
proof-of-concept studies. This impediment can be easily overcome by application of viral vector
which specifically integrates into neutral location in the genome—e.g., so-called “safe harbor” on
chromosome 19 in the case of adeno-associated viruses (AAV) [45]. Generation of suicide gene system
involving AAV and CRISPR/Cas9 is goal of our ongoing study.
We showed that described suicide gene approach is very efficient in selective elimination of cells
expressing HSV-TK. Virtually all genetically modified kiPS cells were eradicated within four days of
treatment with low dose of GCV in vitro. In addition, in vivo tumors generated by kiPS HSV-TK cells
were almost completely eliminated by low doses of GCV, without any systemic toxicity.
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In our bicistronic vector two transgenes were linked by IRES sequence, with HSV-TK as second
cistron, which expression is known to be considerable lower than expression of the first gene [46].
kiPS HSV-TK cells were very efficiently eliminated by GCV in vitro, even compared to our previous
experiments with rhabdmyosarcoma cells, despite weaker promoter applied here (UbC here vs. CMV
in [29]). These observations suggest high vulnerability of iPS cells to toxic GCV metabolite generated
by HSV-TK and feasibility of designed suicide gene therapy of iPS cells. Constitutive promoter
for ubiquitin C applied in generated gene constructs ensures constant and long-term expression of
transgenes in differentiated cells of all types. This is a trait of key meaning in designing life-long
“emergency exit”. Another promising constitutive promoter is Elongation Factor-1-Alpha (EF-1-alpha)
as it guarantees relatively strong and permanent expression of transgene [47].
In another approach, we plan to generate a vector in which expression of suicide gene is driven
by promoter specific for embryonic/pluripotent cells (e.g., NANOG or OCT4). Such approach could
allow eradication of any undifferentiated cells within differentiated cells population derived from iPS
cells before their transplantation and would selectively sensitize putative de- or un- differentiated
cells in transplants. These two tactics (suicide gene-based purification of cells before transplantation
and specific safeguarding of transplanted cells) are other ideas to increase iPS cells’ safety. They can
also be combined with approach described here by use of two separate suicide genes and promoters to
generate “double emergency switch”. Deoxycytidine kinase and cytosine deaminase are examples of
other suicide genes [48,49].
We presented selective elimination of human iPS cells by HSV-TK+GCV system. Safeguarding
of primates iPS cells [49] and human ES cells [50] with suicide genes as well as numerous suicide
gene therapies of cancer cells [27–32,48,51] including phase I clinical trial [52] were already described
proving universal character of described approach.
iPS cells, thanks to their pluripotency, are great promise for future regenerative therapies of many
diseases. However, their pluripotency is also their greatest risk, as their tumorigenic potential must be
overcome before they will advance to clinic. Safety is key matter in regenerative therapy involving
stem cells application.
4. Materials and Methods
4.1. Cell Cultures
Generated keratinocytes-derived induced pluripotent stem cells (kiPS) were routinely cultured
on Gelatin (Sigma-Aldrich, Saint Louis, MO, USA) coated dishes with feeder layer of mitomycin
C (Sigma-Aldrich)-inactivated mouse embryonic fibroblasts (MEFs) in serum-free iPS medium
consisting of DMEM/F12 with 20% KSR, 2 mM GLUTAMAX, 100 µM Non-Essential Amino Acids,
100 U/mL/100 µg/mL Penicillin/Streptomicin, 10 ng/mL bFGF (all from ThermoFisher Scientific,
Waltham, MA, USA) and 100 µM β-mercaptoethanol (Sigma-Aldrich) until confluent. Medium
was changed every day. kiPS cells were subcultured with Accutase (Lonza, Basel, Switzerland)
in proportion 1:4–1:10 and seeded onto fresh feeder layer in presence of 10 µM ROCK inhibitor
Y-27632 (Sigma-Aldrich). For transduction and cell sorting experiments kiPS cells were cultured in
feeder-free conditions on growth factor-reduced Matrigel (Corning, New York, NY, USA)-coated dishes
in MEF-conditioned iPS medium. kiPS cells were cryopreserved in freezing medium consisting of
90% FBS (Eurx, Gdańsk, Poland), 10% DMSO (Sigma-Aldrich), 10 µM Y-27632 in density of 1.5 × 106
cells/mL and after 1 h pre-incubation with 10 µM Y-27632.
MEFs were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4.5 g/L
glucose (Lonza) supplemented with 10% v/v FBS, 2 mM L-glutamine and 100 U/mL/100 µg/mL
Penicillin/Streptomycin antibiotics solution (all from ThermoFisher Scientific). Keratinocytes were
cultured in serum free EpiLife medium (ThermoFisher Scientific) with 100 U/mL/100 µg/mL
Penicillin/Streptomycin. All cells were cultured at 37 ◦C in a humidified atmosphere of 5% CO2.
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4.2. Isolation of Keratinocytes from Plucked Hair
Keratinocytes were isolated from outer root sheath (ORS) of the plucked hair by direct outgrowth
according to the protocol described before [53]. Experimental protocol was approved by Jagiellonian
University Bioethical Committee in Kraków by decision number KBET/173/B/2012. Briefly, hairs
plucked with ORSs form occipital part of the head were rinsed with antibiotic/antimycotic solution
(ThermoFisher), cut and placed onto growth factor-reduced Matrigel (Corning) coated dishes in small
amount of MEF-conditioned iPS medium. On the following days, small portions of medium was
added until large outgrowths of keratinocytes surrounding the hair could be observed. At this stage
medium was changed to EpiLife and cells were subcultured with TrypLE (ThermoFisher Scientific)
and expanded on Matrigel-coated dishes until reprogramming.
4.3. Keratinocytes Reprogramming into iPS Cells
Isolated keratinocytes were infected with Sendai virus-based CytoTune—iPS Reprogramming
kit (ThermoFisher Scientific) [20] according to fibroblast reprogramming manufacturer’s instructions
as follows: 3 × 105 keratinocytes were infected in confluency of 40–60% in Multiplicity of Infection,
MOI of 5:5:5:3 (KLF4:OCT4:SOX2:C-MYC). Twenty-four hours post infection and every other day until
Day 6 post infection, medium was replaced with fresh EpiLife medium. On Day 7 post infection,
cells were seeded onto 100 mm culture dish with gelatin and mitomycin-C inactivated MEF feeder
layer in iPS medium containing 1 mM sodium butyrate (Sigma-Aldrich). From this point, cells were
cultured in 5% O2 and medium was changed daily. First emerging colonies could be observed on day
11. On day 15 sodium butyrate was withdrawn and feeder layer was renewed with fresh mitomycin-C
inactivated MEFs. Between 18 and 35 days after infection, colonies with typical iPS morphology and
expression of alkaline phosphatase (investigated by LiveStain, ThermoFisher Scientific) were manually
transferred with a pipette into separate dishes with fresh feeder layers in iPS medium containing 10 µM
Y-27632. Medium was changed daily until transferred colonies were large enough to be subcultured
with Accutase. A total of 18 colonies were transferred.
4.4. Immunocytochemistry
Cells were rinsed with PBS with Ca2+ and Mg2+ (Lonza) and fixed in 4% paraformaldehyde
(Sigma-Aldrich) in PBS with Ca2+ and Mg2+ (Lonza) for 20 min in room temperature.
After paraformaldehyde removal cells were rinsed three times with PBS with Ca2+ and Mg2+ and
permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) in PBS with Ca2+ and Mg2+ (5 min in room
temperature). Then the cells were rinsed and unspecific binding sites were blocked with 3% BSA in
PBS with Ca2+ and Mg2+ (30 min in room temperature). The cells were incubated with appropriate
antibodies diluted in 3% BSA in PBS with Ca2+ and Mg2+ overnight in 4 ◦C, rinsed three times with
PBS with Ca2+ and Mg2+ and incubated with appropriate fluorescently labelled secondary antibodies
and Hoechst (ThermoFisher Scientific) diluted in 3% BSA in PBS with Ca2+ and Mg2+ for 1 h in room
temperature in the dark. Antibodies and dilutions were as follows: SSEA-3 1:100 (BD, Franklin Lakes,
NJ, USA), SSEA-4, mouse 1:100 (BD, USA), TRA-1-60, rabbit 1:100 (BD), TRA-1-81, mouse 1:100 (BD,
USA). Protein-iPS (piPS, System Biosciences, Palo Alto, CA, USA, [14]) were used as positive control.
4.5. RT-PCR
Gene expression on the level of mRNA was analyzed by RT-PCR. Briefly, total RNA was
isolated with GeneMATRIX Universal RNA kit (Eurx). Reverse transcription (RT) was performed
with M-MLV reverse transcription kit (Promega, Madison, WI, USA) according to manufacturer
instructions. PCR reactions were performed with Taq PCR Master Mix (Eurx). One hundred
nanograms (per reaction) of generated cDNA was used as a template. All used primers were
designed to work optimally at annealing temperature of 55 ◦C. Sequences (5′ to 3′) of used
primers: OCT4 for ATGGCGGGACACCTGGCTT, Oct4 rev GGGAGAGCCCAGAGTGGTGACG,
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NANOG for TGAACCTCAGCTACAAACAG, NANOG rev TGGTGGTAGGAAGAGTAAAG, TERT
for TGTGCACCAACATCTACAAG, TERT rev GCGTTCTTGGCTTTCAGGAT, C-MYC for ATGCC
CCTCAACGTTAGCT, C-MYC rev TTACGCACAAGAGTTCCG, GAPDH for CAAAGTTGTCA
TGGATGACC, GAPDH rev CCATGGAGAAGGCTGGGG, Primers sequence for Sendai virus genome
(SeV) and transgenic c-Myc (vc-Myc) were given by manufacturer in Sendai virus kit manual.
Protein-iPS (piPS, System Biosciences, [14]) were used as a negative control and freshly reprogrammed
sendai virus-iPS (sv-iPS) as a positive control.
4.6. Teratoma Formation
All animal experiments were conducted according to ethical committee guidelines. All experimental
protocols were approved by 2nd Local Institutional Animal Care and Use Committee (IACUC) in
Kraków by decision number 162/2015 on 24 June 2015. Generated kiPS cells were subcutaneously
injected into left dorsal flank of adult female NOD/SCID mice. Cells (3× 106) in 200 µL of PBS/growth
factor-reduced Matrigel (Corning) 1:1 were injected per mice. Growth of tumors and mice health was
monitored every other day.
4.7. Generation and Analysis of Genetically Modified Cells
Lentiviral particles were generated accordingly to ViraPower protocol (ThermoFisher Scientific).
HEK293T cells (9.5 × 106) were seeded in DMEM High Glucose, 10% FBS. Transfection with calcium
orthophosphate was performed four hours after seeding. The transfection mixture was as follows:
26–39 µg of plasmid DNA, 65 µL of 2.5M CaCl2, 650 µL of 2× BBS (BES buffered saline, pH = 7.2)
and 585 µL H2O. Transfection mix was incubated for 20 min in room temperature before transfer
into fresh culture medium with 25 µM chloroquine (Sigma-Aldrich). Lentiviral particles containing
medium was harvested 48 and 72 h after transfection. Harvested medium was centrifuged (3000 rpm,
10 min, 4 ◦C) and filtered through 0.45 µm syringe filter to eradicate remaining HEK293T cells
and ultracentrifuged (25,000× g, 2 h, 4 ◦C) to concentrate the viral particles and transfer them
to serum-free iPS cell medium. Transfection mixtures consisting of either GFP@pLenti6/Ubc or
GFP-ires-HSV-TK@pLenti6/Ubc expression plasmid and pLP1, pLP2, pLP-VSVG packaging plasmids
were prepared. Plasmids GFP@pLenti6/Ubc and GFP-ires-HSV-TK@pLenti6/Ubc were prepared by
cloning GFP or GFP-ires-HSV-TK inserts from pLOX-gfp-ires-HSV-TK plasmid into Gateway pLenti
system (ThermoFisher Scientific) according to manufacturer’s instructions. pLOX-gfp-ires-HSV-TK
plasmid was a gift from Didier Trono (Addgene plasmid #12243). The same copy number (1.5 × 1012)
of both expression plasmids were used. Maps of plasmid applied can be found in Figure S2.
To determine the titer of lentiviral stocks, HT1080 cells were infected. Four hours prior to
transduction, 5× 104 cells were seeded on 24-well plate. Various volumes of condensed virus solutions
(0.1–100 µL) were added to seeded HT1080 cells. Forty-eight hours after transduction the percentages
of modified (GFP-expressing) cells were assessed by Attune flow cytometer (ThermoFisher Scientific)
to calculate Transduction Units (TU) in 1 mL of each harvested medium.
To obtain modified cell lines, iPS cells cultured in feeder-free conditions were infected using
generated lentiviral particles introducing GFP and HSV-TK gene in kiPS HSV-TK cell line or GFP only
in kiPS GFP control cell line. Transduction was performed with MOI = 3 (Multiplicity of Infection)
on 6-well plate. kiPS GFP and kiPS HSV-TK cell lines were selected with 5 µg/mL Blasticidin
(ThermoFisher Scientific) for two weeks and purified using FACS Aria II cell sorter (BD). The percentage
of green fluorescent cells in modified cell lines have been measured by Attune (ThermoFisher Scientific)
flow cytometer.
4.8. Suicide Gene Therapy In Vitro
First, 2.5 × 104 of wild-type (WT) and genetically modified kiPS cells (GFP and HSV-TK) were
seeded onto well of 24-well plate. Four hours after seeding, medium was changed for medium
containing 0.1, 1 and 10 µg/mL ganciclovir or control fresh medium. All medias were changed daily.
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On each of following 5 days, cells in each group (WT, GFP and HSV-TK with or without GCV addition)
were observed to analyze the influence of GCV.
4.9. Xenografts and Suicide Gene Therapy In Vivo
All animal experiments were conducted according to ethical committee guidelines. All experimental
protocols were approved by 2nd Local Institutional Animal Care and Use Committee (IACUC) in
Kraków by decision number 162/2015 on 24 June 2015. kiPS (WT, GFP and HSV-TK) cells were
subcutaneously injected into left dorsal flank of adult female NOD/SCID mice. Cells (3 × 106) in
200 µL of PBS/growth factor-reduced Matrigel (Corning) 1:1 were injected per mice. Tumors growth
and mice health was monitored every other day. When tumors become measurable mice in each group
(n = 6) were randomly divided into two regimes: receiving 1 mg of ganciclovir in 0.5 mL PBS (50 mg/kg
of body weight) and receiving only 0.5 mL PBS (n = 3). Both groups were injected intraperitoneally,
daily for 42 days. After this period, mice were sacrificed, tumors and internal organs (liver, kidney,
spleen, lungs, brains and hearth) were isolated and fixed in 40% paraformaldehyde. Tumors were
measured and weighed. Fixed tissues were imbedded in paraffin, cut, stained with hematoxylin/eosin
and analyzed histopathologically. Volume (v) of tumors was calculated with equation v = 1/2 ab2,
where a and b are measured tumor sizes.
4.10. Statistical Analysis
Statistical analysis of acquired data was performed with STATISTICA 10.0. Software (StatSoft,
Tulsa, OK, USA). Mann–Whitney U-test or Kruskal–Wallis tests were applied to verify statistically
relevant differences between experimental groups. Data are presented as mean ± standard error.
Statistically significant differences (p < 0.05) were marked with *.
5. Conclusions
We showed that iPS cells can be conveniently acquired by safe reprograming of plucked-hair
keratinocytes. Generated in patient-specific manner iPS cells can be genetically secured with suicide
gene, which introduces an “emergency exit” allowing easy, fast and efficient eradication of transplanted
cells upon their undesired behavior. We believe that described approach increases safety of iPS cells
and brings them one step closer to clinical application.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/1/197/s1.
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